Patent: 10,363,307
✉ Email this page to a colleague
Summary for Patent: 10,363,307
| Title: | Methods of treating psoriatic arthritis using IL-17 antagonists |
| Abstract: | The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). |
| Inventor(s): | Mpofu; Shephard (Oberwil, CH), Richards; Hanno (Therwil, CH), Thangavelu; Karthinathan (Geneva, CH), Machacek; Matthias (Allschwil, CH) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 15/654,854 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,363,307
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | January 21, 2015 | 10,363,307 | 2037-07-20 |
| Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | For Injection | 125504 | January 21, 2015 | 10,363,307 | 2037-07-20 |
| Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | May 28, 2021 | 10,363,307 | 2037-07-20 |
| Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | May 11, 2023 | 10,363,307 | 2037-07-20 |
| Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 761349 | October 06, 2023 | 10,363,307 | 2037-07-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
